|
1
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Branger DF, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues
P and Ellison DW: The 2016 world health organization classification
of tumors of the central nervous system: A summary. Acta
Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hawkins-Daarud A, Rockne RC, Anderson AR
and Swanson KR: Modeling tumor-associated edema in gliomas during
anti-angiogenic therapy and its impact on imageable tumor. Front
Oncol. 3:662013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin L, Cai J and Jiang C: Recent advances
in targeted therapy for glioma. Curr Med Chem. 24:1365–1381. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Navarro L, Gil-Benso R, Megías J,
Muñoz-Hidalgo L, San- Miguel T, Callaghan RC, González-Darder JM,
López-Ginés C and Cerdá-Nicolás MJ: Alteration of major vault
protein in human glioblastoma and its relation with EGFR and PTEN
status. Neuroscience. 297:243–251. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al:
Malignant astrocytic glioma: Genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Inda MM, Bonavia R, Mukasa A, Narita Y,
Sah DW, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, et
al: Tumor heterogeneity is an active process maintained by a mutant
EGFR-induced cytokine circuit in glioblastoma. Genes Dev.
24:1731–1745. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Muñoz-Hidalgo L, San-Miguel T, Megías J,
Monleón D, Navarro L, Roldán P, Cerdá-Nicolás M and López-Ginés C:
Somatic copy number alterations are associated with EGFR
amplification and shortened survival in patients with primary
glioblastoma. Neoplasia. 22:10–21. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Benito R, Gil-Benso R, Quilis V, Perez M,
Gregori-Romero M, Roldan P, Gonzalez-Darder J, Cerdá-Nicolas M and
Lopez-Gines C: Primary glioblastomas with and without EGFR
amplification: Relationship to genetic alterations and
clinicopathological features. Neuropathology. 30:392–400. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Akizuki K, Sekine M, Kogure Y, Kameda T,
Shide K, Koya J, Kamiunten A, Kubuki Y, Tahira Y, Hidaka T, et al:
TP53 and PTEN mutations were shared in concurrent germ cell tumor
and acute megakaryoblastic leukemia. BMC Cancer. 20:52020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Solbach C, Roller M, Fellbaum C, Nicoletti
M and Kaufmann M: PTTG1 mRNA expression in primary breast cancer: A
prognostic marker for lymph node invasion and tumor recurrence.
Breast. 13:80–81. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Zhou LP, Ma P, Sui CG, Meng FD, Tian
X, Fu LY and Jiang YH: Relationship of PTTG1 expression with tumor
invasiveness and microvessel density of pituitary adenomas: A
meta-analysis. Genet Test Mol Biomarkers. 18:279–285. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ramaswamy S, Ross KN, Lander ES and Golub
TR: A molecular signature of metastasis in primary solid tumors.
Nat Genet. 33:49–54. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cui LS, Lin T, Xu LX, Wang GL, Lin JB,
Feng SP, Cao Y, Cao Y, Song ZM and Jin X: The effect of
down-regulated gene PTTG11 on proliferation, apoptosis, migration
and invasion of human glioma cell SHG44. China Oncol. 29:338–344.
2019.
|
|
15
|
Johnston PA and Grandis JR: STAT3
signaling: Anticancer strategies and challenges. Mol Interv.
11:18–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tu Y, Zhong Y, Fu J, Cao Y, Fu G, Tian X
and Wang B: Activation of JAK/STAT signal pathway predicts poor
prognosis of patients with gliomas. Med Oncol. 28:15–23. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tan MSY, Sandanaraj E, Chong YK, Lim SW,
Koh LW, Ng WH, Tan NS, Tan P, Ang BT and Tang C: A STAT3-based gene
signature stratifies glioma patients for targeted therapy. Nat
Commun. 10:36012019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ouedraogo ZG, Biau J, Kemeny JL, Morel L,
Verrelle P and Chautard E: Role of STAT3 in genesis and progression
of human malignant gliomas. Mol Neurobiol. 54:5780–5797. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang N, Ahn SH, Kong DS, Lee HW and Nam
DH: The role of STAT3 in glioblastoma progression through dual
influences on tumor cells and the immune microenvironment. Mol Cell
Endocrinol. 451:53–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Siddiquee K, Zhang S, Guida WC, Blaskovich
MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence
NJ, et al: Selective chemical probe inhibitor of Stat3, identified
through structure-based virtual screening, induces antitumor
activity. Proc Natl Acad Sci USA. 104:7391–7396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou C, Tong Y, Wawrowsky K and Melmed S:
PTTG1 acts as a STAT3 target gene for colorectal cancer cell growth
and motility. Oncogene. 33:851–861. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sarper SE, Inubushi T, Kurosaka H, Minagi
HO, Kuremoto KI, Sakai T, Taniuchi I and Yamashiro T: Runx1-Stat3
signaling regulates the epithelial stem cells in continuously
growing incisors. Sci Rep. 8:109062018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Segatto I, Berton S, Sonego M, Massarut S,
Perin T, Piccoli E, Colombatti A, Vecchione A, Baldassarre G and
Belletti B: Surgery-Induced wound response promotes stem-like and
tumor-initiating features of breast cancer cells, via STAT3
signaling. Oncotarget. 5:6267–6279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Su W, Guo C, Wang L, Wang Z, Yang X, Niu
F, Tzou D, Yang X, Huang X, Wu J, et al: LncRNA MIR22HG abrogation
inhibits proliferation and induces apoptosis in esophageal
adenocarcinoma cells via activation of the STAT3/c-Myc/FAK
signaling. Aging (Albany NY). 11:4587–4596. 2019.PubMed/NCBI
|
|
25
|
Guha P, Gardell J, Darpolor J, Cunetta M,
Lima M, Miller G, Espat NJ, Junghans RP and Katz SC: STAT3
inhibition induces bax-dependent apoptosis in liver tumor
myeloid-derived suppressor cells. Oncogene. 38:533–548. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chuang PY and He JC: JAK/STAT signaling in
renal diseases. Kidney Int. 78:231–234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Banerjee K and Resat H: Constitutive
activation of STAT3 in breast cancer cells: A review. Int J Cancer.
138:2570–2578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhi T, Jiang K, Xu X, Yu T, Zhou F, Wang
Y, Liu N and Zhang J: ECT2/PSMD14/PTTG11 axis promotes the
proliferation of glioma through stabilizing E2F1. Neuro Oncol.
21:462–473. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luwor RB, Baradaran B, Taylor LE, Iaria J,
Nheu TV, Amiry N, Hovens CM, Wang B, Kaye AH and Zhu HJ: Targeting
stat3 and smad7 to restore TGF-beta cytostatic regulation of tumor
cells in vitro and in vivo. Oncogene. 32:2433–2441. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Boelaert K, McCabe CJ, Tannahill LA,
Gittoes NJ, Holder RL, Watkinson JC, Bradwell AR, Sheppard MC and
Franklyn JA: Pituitary tumor transforming gene and fibroblast
growth factor-2 expression: Potential prognostic indicators in
differentiated thyroid cancer. J Clin Endocrinol Metab.
88:2341–2347. 2003. View Article : Google Scholar : PubMed/NCBI
|
